ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Dear All,Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR; 1 Oct 2024 newsletter and our dedicated UNGA 2024 webpage), you will hopefully recall the commitment to create an Independent Panel on Evidence for Action against AMR (IPEA).The broad idea is the data from an independent panel would have great credence and encourage governmental action. The importance of creating of an IPEA was specifically noted in paper #4 from the 10-20-30 Lancet series (Mendelson et al. Lancet 2024 and the 23 May 2024 newsletter) and has been supported by funding promises of €2.5 million from the European Commission along with commitments of GBP 10 million each from the United Kingdom and Saudi Arabia.And the hope is that this will move quickly. A roadmap released 14 Mar 2025 calls for work to ensure that the IPEA "is established and commences its work as soon as practicable in 2025."So, how do you create an IPEA? How is it organized? How is it governed? To answer that question, we today have papers from the Quadripartite Joint Secretariat on AMR (QJS) on possible ways to create an IPEA ... and we are all invited to comment on the best approach. Here are the...
Dear All,Attention phage developers --...
Dear All,D-Day and the momentous Normandy...
Latest Government Action
Dear All,Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR; 1 Oct 2024 newsletter and our dedicated UNGA 2024 webpage), you will hopefully recall the commitment to create an Independent Panel on Evidence for Action against AMR (IPEA).The broad idea is the data from an independent panel would have great credence and encourage governmental action. The importance of creating of an IPEA was specifically noted in paper #4 from the 10-20-30 Lancet series (Mendelson et al. Lancet 2024 and the 23 May 2024 newsletter) and has been supported by funding promises of €2.5 million from the European Commission along with commitments of GBP 10 million each from the United Kingdom and Saudi Arabia.And the hope is that this will move quickly. A roadmap released 14 Mar 2025 calls for work to ensure that the IPEA "is established and commences its work as soon as practicable in 2025."So, how do you create an IPEA? How is it organized? How is it governed? To answer that question, we today have papers from the Quadripartite Joint Secretariat on AMR (QJS) on possible ways to create an IPEA ... and we are all invited to comment on the best approach. Here are the...
Dear All,Attention phage developers --...
Dear All,D-Day and the momentous Normandy...
Dear All,If you represent a...
Dear All, Sadly, I must...
Dear All (and with thanks...
R&D Insight
Dear All (and with thanks...
Dear All,I hope everyone is...
Dear All,We learned today during...
Dear All: Potpourri! Four things...
Dear All: Two papers (one...
Can you help?
Dear All,I have just learned that Lifeline, the musical formerly known as The Mould that Changed the World, is seeking scientists, medics, and healthcare professionals to be part of the cast for a portion of a planned 5-week off-Broadway run of the show around the time of the High-Level Meeting (HLM) on AMR at UNGA 2024 in New York City...
Dear All, Heads up! Having...
Note: Be sure to take...
Update on 11 October 2023: The...
Dear All,Along with more than...
Dear All (and with thanks to...
Dear All, Two items for...
Dear All, Three things today......
Dear All, Greetings from ECCMID...
Dear All,A key theme of...
Dear All,Following hard on the...
Dear All, A short one...
Dear All, We are swimming...
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
AMR Fireside Chats
1/18 videos
1
Episode 17 w/ Ella Balasa and Rob Purdie of WHO Task Force of AMR Survivors - AMR Fireside Chat
38:24
2
Episode 16 w/ Ramanan Laxminarayan, PhD - AMR Fireside Chat
32:59
3
Episode 15 w/ Mark Albrecht, PhD - AMR Fireside Chat
43:55
4
Episode 14 w/ Lynn Silver - AMR Fireside Chat
56:23
5
Episode 13 w/ Kevin Outterson - AMR Fireside Chat
30:01
6
Episode 12 w/ Tina Joshi, PhD - AMR Fireside Chat
34:22
7
Episode 11 w/ Martin Heidecker - AMR Fireside Chat
32:31
8
Episode 10 w/ Anna Govett - AMR Fireside Chat
14:54
9
Episode 9 w/ Fatema Rafiqi, PhD - AMR Fireside Chat
34:10
10
Episode 8 w/ Ghada Zoubiane, PhD - AMR Fireside Chat
35:04
11
Episode 7 w/ Trevor Lithgow, PhD - AMR Fireside Chat
35:41
12
AMR Snapshots: Episode 2 - John Rex (Editor-In-Chief, AMR.Solutions)
26:25
13
Episode 6 w/ Maryn McKenna - AMR Fireside Chat
45:50
14
Episode 5 w/ Christine Årdal - AMR Fireside Chat
43:44
15
Episode 4 w/ Peter Beyer - AMR Fireside Chat
39:21
16
Episode 3 w/ Kevin Outterson - AMR Fireside Chat
11:45
17
Episode 2 w/ Henry Skinner, PhD - AMR Fireside Chat
15:44
18
Episode 1 w/ Kevin Outterson - AMR Fireside Chat
52:56
FDA workshop: Insights on inhaled antifungals and antibacterials
Dear All (wonkish alert … coffee up!), FDA held a workshop on 25 Sep 2020 on development of inhaled antifungal (AF) therapies with a focus ...
Read More →
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
Dear All (detailed and wonkish note alert … lots of thinking out loud … get some coffee and settle in!), I wrote previously (link) about ...
Read More →
NIAID workshop: What is a robust PK-PD package?
Dear All: The ~150 of us who gathered in Washington yesterday and today for the NIAID’s PK-PD workshop enjoyed a very rich conversation. It’s really ...
Read More →
Modeling the value of an effective antibiotic — Megiddo et al.
Dear All: I have previously written about the challenge of applying health technology assessment (HTA) to estimate the monetary value of an effective antibiotic: To my knowledge, ...
Read More →
The 6 meanings of “Lack of Access” (UNSLAP)
Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year ...
Read More →
The hunt for oral antibiotics: Beyond Lipinski’s Rule of Five
Dear All: Given our collective interest in finding oral antibiotics, a recent article in J Med Chem on the evolution of our understanding of Lipinski’s ...
Read More →
FDA analysis of 40-years of antibacterial development: Dheman et al.
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Just out in CID is a paper in which FDA analyzes trends in ...
Read More →
In Praise of Non-Inferiority
Dear All (wonkish but intended for everybody to read and absorb): 27 Jan 2021 update: This topic now has its own YouTube video! As the ...
Read More →
COVID-19 and the Long-Term Trajectory of AMR Efforts: Wellcome Trust Deep Dive
Dear All (Wonkish alert! Coffee-up!), Today we have something special: A deep-dive into the future trajectory of AMR-related work developed by Wellcome Trust. The newly ...
Read More →
Plazomicin EU marketing application is withdrawn: Near zero market value of newly approved antibacterials
Dear All (with thanks to Kevin Outterson for co-authoring this newsletter), Last week’s announcement of the AMR Action Fund was both exciting and sobering: $1b ...
Read More →
Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House
Dear All (wonkish alert, but the details are fascinating … and with thanks to Kevin Outterson for co-authoring!), Two related items of note for today. ...
Read More →
Push! Pull! Push! Pull! / Highlights from Davos 2018
Dear All: Three important documents were released at / during / around the World Economic Forum meeting that occurred this week in Davos. First and foremost, ...
Read More →
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
Summaries
Notes: Newsflash ... BARDA have...
Aside: If you've enjoyed the...
See also This related newsletter:...
Dear All (and with thanks...
Dear All (Wonkish alert! Coffee-up!),Today...